SG10201602111VA - Formulations Comprising Methylthioninium Chloride - Google Patents

Formulations Comprising Methylthioninium Chloride

Info

Publication number
SG10201602111VA
SG10201602111VA SG10201602111VA SG10201602111VA SG10201602111VA SG 10201602111V A SG10201602111V A SG 10201602111VA SG 10201602111V A SG10201602111V A SG 10201602111VA SG 10201602111V A SG10201602111V A SG 10201602111VA SG 10201602111V A SG10201602111V A SG 10201602111VA
Authority
SG
Singapore
Prior art keywords
formulations
methylthioninium chloride
methylthioninium
chloride
Prior art date
Application number
SG10201602111VA
Inventor
Karrar Ahmad Khan
Original Assignee
Wista Lab Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wista Lab Ltd filed Critical Wista Lab Ltd
Publication of SG10201602111VA publication Critical patent/SG10201602111VA/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/5415Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1629Organic macromolecular compounds
    • A61K9/1652Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2095Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841Filling excipients; Inactive ingredients
    • A61K9/4866Organic macromolecular compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02Muscle relaxants, e.g. for tetanus or cramps
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D279/00Heterocyclic compounds containing six-membered rings having one nitrogen atom and one sulfur atom as the only ring hetero atoms
    • C07D279/101,4-Thiazines; Hydrogenated 1,4-thiazines
    • C07D279/141,4-Thiazines; Hydrogenated 1,4-thiazines condensed with carbocyclic rings or ring systems
    • C07D279/18[b, e]-condensed with two six-membered rings
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
SG10201602111VA 2010-11-30 2011-11-30 Formulations Comprising Methylthioninium Chloride SG10201602111VA (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US41816410P 2010-11-30 2010-11-30

Publications (1)

Publication Number Publication Date
SG10201602111VA true SG10201602111VA (en) 2016-04-28

Family

ID=45418703

Family Applications (2)

Application Number Title Priority Date Filing Date
SG2013040357A SG190406A1 (en) 2010-11-30 2011-11-30 Formulations comprising methylthioninium chloride
SG10201602111VA SG10201602111VA (en) 2010-11-30 2011-11-30 Formulations Comprising Methylthioninium Chloride

Family Applications Before (1)

Application Number Title Priority Date Filing Date
SG2013040357A SG190406A1 (en) 2010-11-30 2011-11-30 Formulations comprising methylthioninium chloride

Country Status (10)

Country Link
US (1) US9192611B2 (en)
EP (1) EP2645994B1 (en)
JP (1) JP6093707B2 (en)
CN (1) CN103379901B (en)
AU (1) AU2011334679B2 (en)
CA (1) CA2818068C (en)
ES (1) ES2655492T3 (en)
MY (1) MY163074A (en)
SG (2) SG190406A1 (en)
WO (1) WO2012072977A2 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014153444A (en) * 2013-02-06 2014-08-25 Konica Minolta Inc Retardation film, polarizing plate, and liquid crystal display
SI3487505T1 (en) 2016-07-25 2023-10-30 Wista Laboratories Ltd., Administration and dosage of diaminophenothiazines
FR3104438B1 (en) 2019-12-12 2021-11-19 Univ Bordeaux FORMULATION FOR METHYLENE BLUE AND PROCESS
WO2023232764A1 (en) 2022-05-31 2023-12-07 Wista Laboratories Ltd. Treatment of neurodegenerative disorders utilising methylthioninium (mt)-containing compounds
WO2024063700A1 (en) 2022-09-21 2024-03-28 Yin Sze Loh Oral formulation of diaminophenothiazines and methods of making and using the same in the treatment and/or prevention of diseases

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4880373A (en) 1988-04-28 1989-11-14 The Upjohn Company Tablet press
JPH0840942A (en) * 1994-07-29 1996-02-13 Kanegafuchi Chem Ind Co Ltd Drug-release controlled preparation
GB9506197D0 (en) 1995-03-27 1995-05-17 Hoffmann La Roche Inhibition of tau-tau association.
GB0101049D0 (en) 2001-01-15 2001-02-28 Univ Aberdeen Materials and methods relating to protein aggregation in neurodegenerative disease
GB0106953D0 (en) 2001-03-20 2001-05-09 Univ Aberdeen Neufofibrillary labels
GB0322756D0 (en) 2003-09-29 2003-10-29 Univ Aberdeen Methods of chemical synthesis
JP5186212B2 (en) * 2004-09-23 2013-04-17 ウィスタ ラボラトリーズ リミテッド Method for chemical synthesis and purification of diaminophenothiazinium compounds such as methylthioninium chloride (MTC)
DK2322517T3 (en) 2004-09-23 2019-06-11 Wista Lab Ltd METHODS FOR CHEMICAL SYNTHESIS AND CLEANING OF DIAMINOPHENOTHIAZINUM COMPOUNDS WITH METHYLTHIONINUMCHLORID (MTC)
EP1811957B1 (en) * 2004-10-19 2008-11-26 KRKA, tovarna zdravil, d.d., Novo mesto Solid pharmaceutical composition comprising donepezil hydrochloride
EP1919456A2 (en) * 2005-08-24 2008-05-14 Wyeth a Corporation of the State of Delaware Bazedoxifene acetate formulations and manufacturing process thereof
CA2627695A1 (en) * 2006-01-05 2007-07-19 Teva Pharmaceutical Industries Ltd. Dry formulations of aripiprazole
PT2013191E (en) 2006-03-29 2010-10-29 Wista Lab Ltd 3,7-diamino-10h-phenothiazine salts and their use
US20080317678A1 (en) * 2007-06-22 2008-12-25 Szymczak Christopher E Laser Marked Dosage Forms
ES2546819T3 (en) 2007-10-03 2015-09-28 Wista Laboratories Ltd. Therapeutic use of diaminophenothiazines
WO2009060191A2 (en) 2007-11-05 2009-05-14 Wista Laboratories Ltd. Systems for clinical trials
AU2010299574B2 (en) * 2009-09-24 2013-09-26 Wista Laboratories Ltd. Process

Also Published As

Publication number Publication date
AU2011334679A1 (en) 2013-07-18
CA2818068A1 (en) 2012-06-07
CA2818068C (en) 2019-06-11
EP2645994B1 (en) 2017-11-01
EP2645994A2 (en) 2013-10-09
JP6093707B2 (en) 2017-03-08
US9192611B2 (en) 2015-11-24
WO2012072977A8 (en) 2012-09-20
CN103379901A (en) 2013-10-30
ES2655492T3 (en) 2018-02-20
CN103379901B (en) 2018-04-03
MY163074A (en) 2017-08-15
JP2013544272A (en) 2013-12-12
WO2012072977A3 (en) 2012-08-16
SG190406A1 (en) 2013-06-28
WO2012072977A2 (en) 2012-06-07
AU2011334679B2 (en) 2016-12-15
US20130243858A1 (en) 2013-09-19

Similar Documents

Publication Publication Date Title
HUS2100005I1 (en) Methylthioninium chloride
GB201205984D0 (en) No details
AU334223S (en) Insole
GB201112400D0 (en) No details
IL222637A0 (en) Alcohol-resistant formulations
ZA201206589B (en) Incotine containing formulation
HK1173368A1 (en) Pigmentation-preventing or-ameliorating agent
GB201015822D0 (en) Medical ruggedised case
SG10201602111VA (en) Formulations Comprising Methylthioninium Chloride
PL2359816T3 (en) Aripiprazole formulations
ZA201300194B (en) Formulations
AU332833S (en) Insole
GB201110193D0 (en) Formulations
GB201013513D0 (en) Formulations
GB201202348D0 (en) No details
GB201105908D0 (en) No details
ZA201300196B (en) Formulations
GB201006326D0 (en) Formulation
GB201018648D0 (en) Formulations
GB201018645D0 (en) Formulations
GB201018647D0 (en) Formulations
GB201018649D0 (en) Formulations
GB201012589D0 (en) Formulations
GB201010494D0 (en) Formulations
GB201008470D0 (en) Formulations